What are your top takeaways from ASN Kidney Week 2025?

1 Answers

Mednet Member

Nephrology · Geisinger Commonwealth School of Medicine

Atacicept (ORIGIN Phase 3 Trial)
Result: At 36 weeks, atacicept achieved a 46% reduction in proteinuria from baseline and 42% vs placebo (p<0.0001). Safety profile was favorable, with fewer serious adverse events than placebo.
First large-scale evidence that dual BAFF/APRIL inhibition can modify dis...